Key Takeaways
- Record revenue, margin dip on investment: Revenue hit a quarterly high of ₹2,772 crores, but EBITDA margin fell 60 bps to 11.4% as the company deliberately increased brand and digital spending.
- Tariff overhang is only partly resolved: The first 10% U.S. duty has been passed through, but negotiations on the subsequent 20% and 50% tranches are still in process, with the outcome expected in the next two months.
- Organic business is absorbing multiple hits: Non-Basmati global price pressure, European private-label transition costs, and pre-shipment ahead of tariff hikes all compressed organic margins, with a recovery promised only by Q4.
- Acquisition-led expansion continues: The company signed an SHA for a Hungary-based processed food acquisition (€25 mn EV) and inaugurated a Rotterdam facility for Nature Bio Foods, both aimed at building a European manufacturing and B2C footprint.
- What to watch next quarter: Whether the delayed U.S. RTC/RTE second unit actually starts production, the outcome of tariff negotiations with U.S. customers, and any sign that organic margins are beginning their promised climb back to historical levels.
Revenue & Profitability
- Top-line composition: The ₹2,772 crores quarterly revenue was the highest ever, driven by brand investments, distribution gains, and the consolidation of Golden Star, which alone added ₹353 crores.
- Organic revenue was flat sequentially: On a QoQ basis, organic revenue was largely unchanged, though H1 still showed 26% growth.
- Gross margin improved: Input costs were stable because 70–80% of the crop is sourced in a single October–February window, so the improvement reflects pricing power and crop efficiency rather than commodity tailwinds.
- PAT margin compressed sharply: PAT margin fell to 6.3% from 7.2%, pulled down by tariff-related pass-through revenue, Nature Bio Foods underperformance, higher brand investment as a percentage of revenue, digital initiative spending, and the changed profit composition from Golden Star's consolidation.
- Other income fell: The decline came because income from Golden Star that previously sat as a share of profit is now consolidated into the operating line.
- Working capital stretched: Payable days rose from 19 to 30 days, attributed to better vendor negotiations.
Rohan Grover: "It will take one more quarter to settle down. But by the end of the year, we believe that in the fourth quarter, we will be back with our margin structures that we have been enjoying for the past few years."
U.S. Tariff Exposure
- Three-phase duty structure: The U.S. imposed tariffs in three steps: an initial 10%, then an additional 25%, then a further 25% to reach 50%. Only the first 10% phase has been fully negotiated and passed on to customers.
- The next two phases are unresolved: Negotiations with customers on the 20% and 50% duty components are still in process, and management expects the next two months to determine the outcome.
- Pre-shipment added to organic margin pressure: Some shipments were preponed to the U.S. ahead of the tariff increases, which contributed to the organic segment's margin dip.
- Christmas inventory is in place: Stocks are fully available on shelves in the U.S. for the holiday season, so near-term volume disruption is not a concern.
Ashwani Kumar Arora: "So, there are two parts of duty. First the 10% duty was imposed, then 25% and then 50%. So, the first phase duty we have negotiated and we have passed on and the impact is of that. Now duty of 20%, 50% that we are in the process of negotiation with our customer."
Segment & Geographic Dynamics
- Organic segment margins under dual pressure: Non-Basmati global prices fell because India's export ban created surplus inventory globally, forcing the company to sell inventory harvested at higher prices into a weaker market. Simultaneously, the European private-label business moved operations to a third party, incurring extra transition costs.
- Middle East recovering from a deep Q1 drop: The region saw a ~33% decline in Q1 but improved sequentially in Q2; management is building the market from a greenfield position and has a five-year ambition to create a sizable business there.
- RTC/RTE demand outstrips supply: Revenue from the ready-to-cook/ready-to-eat segment comes mainly from the U.S., where demand is growing but a second production unit built last year has been delayed, preventing the company from capturing the available demand.
- RTC/RTE margin decline was promotional, not structural: The margin drop in this segment came from incremental brand investments and promotions to accelerate sales, not from third-party manufacturing costs.
- India brand investment doubled: Daawat is the second-largest brand in India, growing at 13%, with household penetration increasing; advertising investment doubled in H1.
- Volume growth data withheld: Management declined to provide volume growth figures for the U.S. and India in 1HFY26, directing the analyst to contact the team.
Acquisitions & Capacity Expansion
- European processed-food acquisition signed: LT Foods signed a shareholders' agreement for a 100% acquisition of Hungary-based Global Green Kft at an enterprise value of €25 million, all-cash. The transaction awaits Hungarian government approval and will consummate 2–3 months after that approval is received.
- Third manufacturing hub created: The Hungary acquisition establishes a third manufacturing hub, reinforcing the company's footprint across Central and Southern Europe. The target had been financially constrained and was not growing, though the category itself is growing.
- Rotterdam B2C facility inaugurated: Nature Bio Foods opened a new facility in Rotterdam to enter the European B2C segment, with initial capex of ~₹20 crores and an additional ₹15 crores planned over the next three years. Revenue acceleration is expected from FY27, with an estimated ₹400 crores in incremental revenue over five years.
- U.S. RTC/RTE capacity doubled but delayed: Capacity has been doubled, but the second unit's production launch is delayed by 6–9 months. Management expects the unit to start in Q3 and ramp up in Q4.
- U.K. subsidiary investment: A £0.5 crore investment was made in the step-down subsidiary for leverage improvement and a factory setup in London.
Strategy & Brand Extension
- Core remains specialty Basmati rice: Management is explicit that it is proud to be a specialty Basmati rice company, with the category growing 5–7% year-on-year, and has a plan to grow both the specialty and dry rice businesses.
- Brand extension follows two strengths: The company will grow around Daawat's brand equity and its distribution network. Rice-plus expansions will leverage the Daawat brand, while non-rice acquisitions will be evaluated for distribution synergy.
- Five-year rolling plan for extensions: The company has a five-year rolling plan for brand extensions into portfolios where Daawat and Royal have a "better right to win" and a growth opportunity.
- Daawat Biryani Kit crossed a milestone: The kit surpassed 0.1 crore units in annual consumption, and a new Daawat Thai Green Curry Rice Kit was launched.
Ashwani Kumar Arora: "So, as a company, as a brand, we have two strengths. One is Daawat as a brand. They have a name. And second, we have a distribution. So, as a strategy, we will grow around this."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Organic margin recovery | Return to historical margin structures | By Q4 FY26 |
| RTC/RTE second unit start | Delayed unit begins production | Q3 FY26 |
| RTC/RTE capacity ramp-up | Full capacity available | Q4 FY26 |
| RTC/RTE segment EBITDA break-even | ₹300–₹400 crore EBITDA guidance, break-even deferred by 6–7 months due to production delay | Deferred by 6–7 months |
| Rotterdam facility revenue contribution | ~₹400 crores incremental revenue over five years | Starting FY27 |
| Hungary acquisition consummation | Transaction closes after government approval | 2–3 months post-approval |
| U.S. tariff pass-through outcome | Negotiation result on 20% and 50% duty tranches | Next two months |
| CVD final determination | Public hearing held Sep 16, 2025; final determination extended by one month | Anticipated by Nov 17, 2025 |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Revenue | ₹2,772 cr, +30% YoY (normalized +12% excluding Golden Star and U.S. tariff) |
| EBITDA | ₹316 cr, +24% YoY |
| EBITDA margin | 11.4%, down 60 bps from 12% in Q2 FY25 |
| PAT margin (H1 FY26) | 6.3%, vs 7.2% in H1 FY25 |
| PAT growth (H1 FY26) | +8.7% YoY |
| ROCE | ~22% |
| H1 FY26 revenue | ₹5,273 cr, +25% YoY (normalized +15% excluding Golden Star and U.S. tariff) |
| H1 FY26 EBITDA | ₹619 cr, +20% YoY |
| Normalized volume growth (H1 FY26) | +23%; +18% excluding Golden Star |
| Basmati and specialty rice revenue growth (H1 FY26) | +24% (normalized +11.4% excluding Golden Star and U.S. tariff) |
| Organic segment revenue growth (H1 FY26) | +26% YoY |
| North America revenue growth | +47% YoY (normalized +16% excluding Golden Star and U.S. tariff); 46% of total revenue |
| Royal brand U.S. Basmati rice import share | 61% |
| India revenue growth | +13% YoY; 30% of total revenue |
| Daawat household reach (India) | 56.2 lakh homes as of March 2025, up from 45.56 lakh in March 2023 |
| Europe and UK revenue growth | +31% YoY; 15% of total revenue |
| Middle East and rest of world revenue share | 9% of total revenue; ₹28 cr from Saudi Arabia |
| Golden Star consolidation contribution (H1 FY26) | ₹353 cr in revenue |
| RTC/RTE segment growth | +9% in the quarter |
| Daawat Biryani Kit cumulative consumption | 0.1 cr units since launch |
| Nature Bio Foods Rotterdam facility capex | ~₹20 cr initial; ₹15 cr additional planned over three years |
| Rotterdam facility estimated incremental revenue | ₹400 cr over next five years, acceleration from FY 2026-27 |
| Global Green Kft acquisition enterprise value | €2.5 cr; last year revenue €4 cr |
| Short-term borrowings | ~₹1,200 cr as of September 30, 2025 |
| Cash and bank balances | ~₹600+ cr as of September 30, 2025 |
| Blended cost of borrowing (rupee terms) | ~7% including bank charges |
| Working capital payable days | +15 days YoY improvement |
| Credit rating | CRISIL AA- A1+, positive outlook revised July 2025 |
| CVD final determination date | November 17, 2025 |